Buzz Of Bids By GSK, Sanofi And Merck Get Louder As Piramal, Wockhardt Decline Sell-Off Talks
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Despite repeated denials, market buzz is getting louder that India's Piramal Healthcare is engaged in preliminary negotiations with multinational drug companies like GlaxoSmithKline, Sanofi-Aventis and Merck for a potential sell off
You may also be interested in...
With Huge Debts And Divestment Plans, Wockhardt Chairman Habil Khorakiwala Exhorts Employees To Rise To The Challenge
Ignore “doctored rumors and incorrect information” in media reports, Khorakiwala says in a morale-boosting internal e-mail.
With Huge Debts And Divestment Plans, Wockhardt Chairman Habil Khorakiwala Exhorts Employees To Rise To The Challenge
Ignore “doctored rumors and incorrect information” in media reports, Khorakiwala says in a morale-boosting internal e-mail.
With Huge Debts And Divestment Plans, Wockhardt Chairman Habil Khorakiwala Exhorts Employees To Rise To The Challenge
MUMBAI - These are tough times for Habil Khorakiwala, chairman of Wockhardt, one of India's largest pharmaceutical and biotechnology companies, as he deals with the worst financial crisis that any large Indian drug company has faced in the aftermath of the global economic meltdown